First in class oncolytic artificial virus delivering three immuno-modulators – IL-12/IL-17RA/shRNA-PD-L1 – to create a broad spectrum of activities

Preclinical safety and efficacy demonstrated in multiple animal models using different routes of administration:

• Colorectal cancer (intra-tumoral and intravenous)
• Ovarian cancer (Intra-peritoneal)
• Hepatocellular carcinoma (intra-tumoral)
• Breast cancer, brain cancer and melanoma animal studies are ongoing (intra-tumoral)

Demonstrated robust efficacy in preclinical studies to date:

• Regression of large tumors
• Prevention of tumor recurrence in both CRC and ovarian cancer
• Abscopal effect (efficacy against distal, un-injected tumors)
• Activates broad immune responses through multiple mechanisms of actions
• Significant impact on survival

Multiple efficacy animal studies in breast and melanoma models are in progress.

Current focus on Intra-tumoral delivery:

• Pre-IND meeting with the FDA held on December 2021
• IND is planned to be filed with the FDA in Q2, 2024